Ji-Yeon Kim, Institute of Oncology Research, Seoul National University, Korea, published an article in JU 2015. explored the expression of PBRM1 gene in patients with stage IV renal cell carcinoma and evaluated the effect of PBRM1 on prognosis and some other predictive values. The target population was 53 patients with stage IV or recurrent renal cell carcinoma. Formalin-fixed paraffin-embedded tissue sections were subjected to PBRM1 immunohistochemical analysis. The results showed that 25 of the 53 cases (47%) had high expression of PBRM1 in the tumor. Analysis comparing survival and treatment response in patients with renal cell carcinoma showed that high PBRM1 expression in tumors reduced survival ([median overall survival (OS), 45.0±4.8 vs 23.0±8.3 months; P=.022]; [median OS in patients with clear cell carcinoma, 46.0±4.1 vs 27.0±6.7 months; P=.053]). For treatment outcomes, those with high PBRM1 expression tended to have a low response to mTOR inhibitors (median PFS, 3.0±0.2 vs 1.9±2.3 months; P= .101). Further subgroup analysis, after grouping according to Heng score, revealed that this trend was more pronounced in the relatively high-risk group than in the low-risk group ([median PFS in the low-risk group, 11.6±1.2 vs 7.4±7.4 months; P=.157]; [PFS in the intermediate-risk group, 7.1±24.7 vs 2.9±0.9 months; P=.060]). This study suggests that PBRM1 expression levels are a potential prognostic factor in advanced renal cell carcinoma. They suggested that the determination of PBRM1 expression levels in tumors might be a guide for determining the prognosis and treatment of metastatic renal cell carcinoma.